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Abstract
Background: Neuregulin-1 proteins are related to physiological correlates of Type A in terms of
cardiac reactivity. Furthermore, neuregulin-1 gene (NRG1) may play a role in cardiovascular
disease such as atherosclerosis and coronary heart disease i.e. the suggested "outcomes" of Type
A behavior. Therefore, NRG1 is hypothesized to be associated with Type A behavior.
Methods: The study examined whether Type A behavior pattern is associated with the single
nucleotide polymorphism (SNP) SNP8NRG221533 of the NRG1. The subjects were 631 men and
women participating in the population-based Cardiovascular Risk in Young Finns study in 1992 and
2001. Type A was self-assessed with the Framingham Type A Scale and reassessed nine years later.
Results: Type A was associated with NRG1 genotype. Carriers of genotype CC scored lower on
Type A compared to the others.
Conclusion: Our study has pinpointed a SNP in NRG1 that predicts Type A behavior. As previous
evidence suggests an association for NRG1 with beta-adrenergic stimulation, its role underlying
Type A is discussed.
Background
Type A behavior, originally described as a behavioral pat-
tern comprising impatience, hard driving and a sense of
hurry [1], was considered in the 60s and 70s as a major
behavioral risk factor for coronary heart disease (CHD). It
was believed to have a similar effect on cardiovascular risk
as the more traditional risk factors, such as elevated systo-
lic blood pressure, serum cholesterol, and smoking [2].
In the 1980's, however, most studies failed to confirm an
association between Type A behavior and CHD [3]. In
1999, the review by Hemingway and Marmot [4] con-
cluded that a contribution of Type A behavior in patho-
genesis of CHD has not been scholarly proved, while in
2000's, new evidence on an association between Type A
and atherosclerosis has been, again, elicited [5].
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Vagueness of the Type A concept may at least partly,
explain these conflicting findings. There is a disagreement
whether Type A mainly refers to emotions, attitudes,
behavioral styles, or innate dispositions, and what is the
contribution of those dimensions to the final concept. If
Type A behavior, or any dimension of it, could be
anchored to genetic background, this might establish its
content. More important, identifying functional genes
related to Type A behavior might increase our knowledge
about mechanisms through which Type A could be asso-
ciated with health outcomes. This study was taken with
these purposes. As far as we know, there are no previous
studies that have associated Type A behavior with molec-
ular genetics. For two reasons, neuregulin-1 (NRG1)
might belong to candidate genes to start with. First, neu-
regulin-1 proteins are related to physiological correlates of
Type A in terms of cardiac reactivity. They seem to reduce
excessive beta-adrenergic stimulation, and help to pro-
duce counterbalancing parasympathetic activity [6,7], and
Type A behavior has been linked to the sensitivity of the
beta-adrenergic system [8,9] and sympathetic versus para-
sympathetic balance [10]. Second, NRG1 may play a role
in cardiovascular disease such as coronary heart disease
and atherosclerosis [11] i.e. the suggested "outcomes" of
Type A behavior. The present study examines an associa-
tion of the single nucleotide polymorphism SNP8NRG22
1533 in the NRG1 gene with Type A behavior.
Methods
Participants
The subjects were derived from the ongoing prospective
population based study, called Cardiovascular Risk in
Young Finns. The Young Finns study has followed a ran-
dom sample of 3596 healthy Finnish children and adoles-
cents (3–18 years old at baseline) since 1980 [12].
Genetic data was acquired from a sub-sample of 1600
subjects (missing n = 62). Psychological data on adult
Type A behavior was obtained first in 1992, and again in
2001 when participants were 15–30 and 24–39 years old,
respectively.
Participants under the age of twenty at the first Type A
assessment were excluded, as questions concerning job-
related Type A behavior were not age-appropriate for
them. After this exclusion, psychological data was received
from 631 genotyped participants who had complete Type
A measures from both follow-ups. Of them 276 (43.7%)
were men and 355 (56.3%) women. Participants gave
written informed consent, and the study was approved by
local ethics committees.
NRG1 genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes using a commercially available kit (Qiagen Inc,
Hilden, Germany) and DNA samples were then geno-
typed by employing the 5'exonuclease assay [13]. For the
PCR, primers and allele-specific fluorogenic probes with
conjugated minor groove binder groups were synthesized
in conjugation with Applied Biosystems (Foster City, CA,
USA) using the sequence (SNP8NRG221533) found on
the deCODE Genetics Web site [14] and GenBank (acces-
sion number AF491780). The PCR reaction mixture con-
sisted of genomic DNA, 1 × Universal PCR Master Mix,
900 nM of each primer and 200 nM of each probe. Ampli-
fication was performed using the TaqMan Universal Ther-
mal Cycling Protocol. After PCR, end-point fluorescence
intensity was measured by the ABI Prism 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) and allelic discrimination performed. All
genotyping was performed blinded to participant out-
come. Negative controls (water) and random duplicates
were used as quality control.
Type A behavior assessment
Type A behavior was self-assessed with the Framingham
Type A Scale [15]. The scale is composed of two subscales:
trait-related Type A behavior and job-related Type A
behavior. Trait-related statements are mainly related to
general feelings such as a sense of competitiveness and
hurry e.g. (1) being hard-driving and competitive and (2)
being bossy and dominating. The job-related questions
are directly related to work e.g. (1) work often stretching
an individual to the very limits of their energy and work
capacity and (2) work often staying with an individual so
that they were thinking about work after working hours.
There were five items on trait-related scale and four items
on job-related scale. The mean score of the sub-scales can
be used as a measure of overall Type A. A high score indi-
cated a high amount of Type A behavior. The Cronbach's
alphas ranged from 0.6 to 0.7 for trait-related Type A and
for the overall Type A. Alpha of job-related scale was 0.5.
Statistical analysis
Univariate ANOVAs were used to determine differences
between genotypes in overall Type A behavior and its sub-
scales for measurements in 1992 and 2001 and for the
mean values of the two assessments. Effect sizes were cal-
culated with partial eta squared (η2). Genotypes TT and
TC were combined as mean values of Type A in these gen-
otypes were almost identical (see Table 1). Analyses were
adjusted for age and gender. Data analysis was carried out
using SPSS/Win (Version 15.0) software. The χ2-test was
used for calculation of the Hardy-Weinberg equilibrium.
Results
Sample representativeness
The group with data from all used variables was compared
to the excluded cases with t- and χ2-tests to assess repre-
sentativeness. No differences were found in NRG1 geno-Behavioral and Brain Functions 2008, 4:40 http://www.behavioralandbrainfunctions.com/content/4/1/40
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type frequencies or Type A behavior (tested using the
mean values of the two measurements). However, women
were somewhat overrepresented in the data (56.3% of
included and 49.8% of the excluded participants were
women, p = .003). Included participants were naturally
also older than excluded participants, because of our age
criterion.
Sample characteristics
The percentages of subjects carrying genotypes TT, CT and
CC in the whole genotyped sub-sample (n = 1600, miss-
ing n = 62), were 33.7%, 49.7% and 16.6%, respectively.
The genotype frequencies followed Hardy-Weinberg equi-
librium (p = .83). Table 1 presents means and standard
deviations of trait-related Type A, job-related Type A, and
Total Type A across the NRG1 genotypes.
NRG1 genotype and Type A behavior
NRG1 genotype was significantly associated with trait-
related Type A behavior (p = .01, η2 = .010) and overall
Type A behavior (p = .02, η2 = .009) on first assessment in
1992, genotype CC carriers having lower Type A than oth-
ers. These associations were replicated on second assess-
ment in 2001 (trait-related Type A: p = .05, η2 = .006;
overall Type A: p = .04, η2 = .007) and when Type A was
calculated as the mean of the two assessments in1992 and
2001 (trait-related Type A: p = .01, η2 = .010; overall Type
A: p = .01, η2 = .010). Again genotype CC carriers showed
lower Type A compared to others. Job related Type A was
not associated with NRG1 genotype on either assessment
or in mean of the two assessments (p > .24 in all measure-
ments).
Discussion
Our findings showed that when compared with other gen-
otypes, individuals carrying the genotype CC of NRG1
had lower Type A behavior. This was true with total Type
A and its trait-related subscale.
The trait-related subscale differentiated the genotypes
whereas the job-related subscale did not. This would be in
line with an assumption that trait-related Type A behavior
is more innate and job-related behavior more circumstan-
tial. It should be noted that calculating the total Type A
behavior in the way used, also emphasizes the portion of
trait-related Type A compared to job-related Type A
behavior.
As the etiology of Type A is still unclear, an association
between NRG1 and Type A behavior might provide hints
of the physiological basis of this personality type and
imply a mechanism through which Type A behavior may
have its effect on health. NRG1 plays a part in the survival,
growth and repair of adult cardiomyocytes as a response
to increased workload [16]. It is also crucial in the devel-
opment of the autonomic nervous system [16] and the
heart [17]. Therefore some autonomic or cardiostructural
function of NRG1 could be related to Type A. One intrigu-
ing possibility for explaining the association is the adren-
ergic system. Type A behavior has been associated with
increased sympathetic balance compared to parasympa-
thetic tone [10,18]. It has been linked, in particular, to the
beta-adrenergic system in men, as it has been associated
with greater B2 adrenergic receptor density [8], and in a
more recent study to greater sensitivity to B1 and B2 recep-
tor agonist isoproterenol administered by bolus injection
[9]. In Type A men, isoproterenol has a stronger effect on
the T wave of the cardioelectrogram, and parasympathetic
antagonism of beta-adrenergic stimulation also appears to
be less effective [10].
Neuregulin proteins, on their part, appear to have the
ability to control excessive beta-adrenergic activation. This
is, incidentally, likely to be a key factor in neuregulin's
protective role in heart failure [6,7]. In animal studies,
neuregulin-1 has been shown to induce counterbalancing
parasympathetic activity [7] and to directly reduce con-
tractibility in heart muscle cells [6]. Thus, adrenergic
responses might play a role in the etiology of Type A and
would be an interesting focus of further molecular
research.
It has primarily been through responses to stressors that
Type A has been thought to be pathogenic, even when
considered as risk factor for atherosclerosis [19] and not
just a trigger for coronary events. If Type A behavior is,
indeed, an actual risk factor for atherosclerosis, neuregu-
lin could be involved in additional ways. As mentioned
above, neuregulin has a protective role in heart failure. In
rat cardiomyocytes, neuregulin-1 activates endothelial
Table 1: Characteristics of Type A Measurements in NRG1 Genotypes.
Trait-related Type A1 Job-related Type A1 Total Type A1
TT (n = 214) 2.50 ± 0.50 1.46 ± 0.24 1.98 ± 0.30
TC (n = 311) 2.50 ± 0.47 1.45 ± 0.24 1.98 ± 0.29
CC (n = 106) 2.37 ± 0.46 1.42 ± 0.25 1.90 ± 0.29
Values represent means ± 1 standard deviations.
TT, TC, and CC represent genotypes of neuregulin-1 gene.
1Type A variables present the means of two measurements (1992 and 2001).Behavioral and Brain Functions 2008, 4:40 http://www.behavioralandbrainfunctions.com/content/4/1/40
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nitric oxide synthase [6], and there is evidence that the
nitric oxide synthase has a role in both heart failure and
atherosclerosis [20,21]. Although neuregulin proteins are
beneficial in heart failure, they may, in fact, play a patho-
logical role in atherosclerosis.
Neuregulin has been found to be overexpressed in coro-
nary atherosclerotic lesions in the intima of human blood
vessels, primarily in macrophages [11]. Type A, in turn,
has been associated with coronary atherosclerosis in Spar-
agon's study with male subjects [22] and also with mark-
ers of arteriosclerosis [23]. The different NRG1 genotypes
might, therefore, mark variation in both susceptibility to
Type A and the development of atherosclerosis. This
hypothesis must, however, be considered with caution, as
the link between different NRG1 forms and atheroscle-
rotic factors has not yet been thoroughly investigated.
Limitations
Cronbach's alpha reliabilities of Type A measures were
moderate in size varying mostly between 0.6 – 0.7. Previ-
ously reported reliabilities for overall Type A correspond
to these values [24]. In the current study job-related Type
A had a slightly lower reliability (0.5). Reliabilities for
Type A subscales are seldom reported but it is likely that
their reliabilities are in general somewhat lower than that
of the overall Type A scale's, as subscales have fewer items,
which in turn, has a diminishing effect on Cronbach's
alpha values.
It is important to note that the association between NRG1
genotype and Type A behavior was found in Framingham
Type A. It is known that different Type A measures do not
correlate very strongly as they emphasize different aspects
of the multidimensional concept. The current results sug-
gest an association for NRG1 with Framingham Type A
but not necessarily with Type A behavior defined by other
measures.
Conclusion
To our knowledge, our study is the first to examine molec-
ular genetics and Type A. A genetic component has previ-
ously been suggested on the basis of quantitative genetics
[25]. A follow-up of nine years gives credit to the sugges-
tion that NRG1 might belong to a genetic basis of a stable
Type A personality.
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